Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW Data showing improved effectiveness, adherence and persistence to be presented at the ADA's 78th Scientific Sessions® |
[24-June-2018] |
INDIANAPOLIS, June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity® (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data.1,2 These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions® in Orlando. Trulicity is Eli Lilly and Company's (NYSE: LLY) once-weekly, injectable GLP-1 RA approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity is available in 0.75 mg and 1.5 mg and should be used along with diet and exercise. "We know that people with type 2 diabetes have significantly better glycemic control when they are able to take their medicines as prescribed, but recognize that there are ongoing challenges with ensuring people remain adherent to their treatment," said Qing Huang, PhD, associate director and principal investigator from HealthCore, Inc. "These real-world data show that people starting on once-weekly Trulicity are associated with a higher likelihood of adhering to their treatment regimen and having a lower A1C compared to two other GLP-1 RA options." The retrospective observational study used U.S. claims data of people with type 2 diabetes newly prescribed Trulicity or either liraglutide or exenatide QW to compare how these treatments performed in a real-world setting.1,2 People were matched against key characteristics such as age, gender, location and baseline A1C to ensure balance in comparing the groups. Trulicity consistently showed advantages across all measures, including A1C reductions, adherence (taking treatment as prescribed) and persistence (staying on treatment).1,2 After both six months and one year of treatment, Trulicity provided significantly better glycemic control than liraglutide (mean absolute reduction in A1C in percent)1:
After six months and one year of treatment, Trulicity led to better glycemic control than exenatide QW (mean absolute reduction in A1C in percent)1:
After one year, people taking Trulicity were significantly more likely to follow their treatment regimen and less likely to discontinue treatment than with liraglutide or exenatide QW. People taking Trulicity had significantly lower rates of discontinuing treatment than those taking liraglutide or exenatide QW.2 Trulicity vs. liraglutide
Trulicity vs. exenatide QW
"Once-weekly Trulicity is designed to help people with type 2 diabetes achieve their A1C goals with a simple experience that may help ease the transition to an injectable treatment," said Laura Fernández Landó, MD, medical director, Lilly Diabetes. "These real-world results include one year Trulicity follow-up data and show Trulicity may make it easier for people new to GLP-1 RA treatment to stay on therapy." About the Study Indication and Limitations of Use for Trulicity® Important Safety Information for Trulicity® Tell your healthcare provider if you get a lump or swelling in your neck, have hoarseness, trouble swallowing, or shortness of breath while taking Trulicity. These may be symptoms of thyroid cancer. In studies with rats or mice, Trulicity and medicines that work like Trulicity caused thyroid tumors, including thyroid cancer. It is not known if Trulicity will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not take Trulicity if you or any of your family members have ever had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not take Trulicity if you have had an allergic reaction to dulaglutide or any of the other ingredients in Trulicity. Trulicity should not be used in children under 18 years of age. Trulicity may cause serious side effects, including: Inflammation of your pancreas (pancreatitis). If you have pain in your stomach area (abdomen) that is severe and will not go away, stop taking Trulicity and call your healthcare provider right away. The pain may happen with or without vomiting. It may be felt going from your abdomen through to your back.
Tell your healthcare provider if you:
If you take too much Trulicity, call your healthcare provider or go to the nearest emergency room right away. The most common side effects with Trulicity may include: nausea, diarrhea, vomiting, abdominal pain and decreased appetite. Talk to your healthcare provider about any side effect that bothers you or does not go away. These are not all the possible side effects of Trulicity. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Please click to access Prescribing Information, including Boxed Warning about possible thyroid tumors including thyroid cancer, and Medication Guide. Please see Instructions for Use included with the pen. DG CON ISI 24AUG2017 About Diabetes About Lilly Diabetes About Eli Lilly and Company P-LLY Trulicity® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Trulicity as a treatment of type 2 diabetes, along with diet and exercise, and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study findings to date,that Trulicity will receive additional regulatory approvals or that Trulicity will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. ©LillyUSA, LLC 2018. All rights reserved.
Refer to: Dani Barnhizer: dbarnhizer@lilly.com: 317-607-6119
View original content with multimedia:http://www.prnewswire.com/news-releases/real-world-data-show-advantages-in-people-treated-with-lillys-once-weekly-trulicity-dulaglutide-compared-to-those-treated-with-liraglutide-and-exenatide-qw-300671061.html SOURCE Eli Lilly and Company | ||||||||||||
Company Codes: NYSE:LLY |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}